Search Results 801-810 of 17360 for alopecia

  1. Mayo Clinic

    ... . IMG-20459884. Home; Pulmonary update cover. 5X Challenge is here! 5X My Gift! Your gift today can have 5X the impact on AI research and technology.

  2. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with Relapsed and Lenalidomide-Refractory Multiple Myeloma - Mayo Clinic

    Ongoing toxicity from previous anticancer therapy that has not resolved to baseline levels or to Grade 1 or less, except for alopecia,; Participants with ...

  3. Mayo Clinic Care Network

    Mayo Clinic and doctors worldwide work together to solve complex medical challenges.

  4. Mayo Clinic

    About Mayo Clinic · About this Site · Contact Us · Locations · Health Information Policy · Medicare Accountable Care Organization (ACO) · Media Requests · News Network.

  5. Improving Access to Care Through the Establishment of a Local, Teledermatology Network - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  6. A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) - Mayo Clinic

    Recovery to ≤ Grade 1 of any clinically significant toxicity (excluding alopecia) rior to randomization. Subject must have adequate bone marrow, renal and ...

  7. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

    Recovery to ≤ Grade 1 or baseline of any non-hematological toxicities due to previous therapy, except alopecia and peripheral neuropathy. Females of ...

  8. A Study Evaluating the Effectiveness and Safety of Axicabtagene Ciloleucel in Subjects with High-Risk Large B-Cell Lymphoma - Mayo Clinic

    Toxicities due to prior therapy must be stable and recovered to Grade 1 or less (except for clinically non-significant toxicities such as alopecia). Age 18 ...

  9. Novel Study Interventions and Combinations in Participants with Colorectal Cancer - Mayo Clinic

    Any unresolved toxicity NCI CTCAE Grade ≥ 2 from a previous anticancer therapy, with the exception of alopecia, vitiligo, and the laboratory values defined ...

  10. Carboplatin and Gemcitabine Hydrochloride With or Without VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Mayo Clinic

    ... alopecia. Patients with treatment related effects, such as peripheral neuropathy, that are grade 1 or less are eligible. Prior exposure to gemcitabine ...